CEACAM5 (CD66e) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the CEACAM family. Key characteristics include:
Several anti-CEACAM5 antibodies with therapeutic potential have been developed:
Generation: Produced by immunizing mice with live LS174T colorectal cancer cells .
Specificity: Binds strongly to colorectal adenocarcinoma tissues .
Therapeutic Efficacy:
Generation: Developed using primary-cultured colorectal cancer spheroids .
Mechanism: Targets glycan structures on CEACAM5/CEACAM6; disrupts integrin β4 signaling .
Functional Impact:
While no trials for "ECM5" exist, related antibodies against CEACAM family members have been tested:
Recent methodologies enhance antibody generation and diversification:
Recombinant Antibody Production:
ECM Scaffold Delivery:
KEGG: sce:YMR176W
STRING: 4932.YMR176W
ECM5 (Extra Cellular Mutant 5) is a protein found in Saccharomyces cerevisiae that plays roles in chromatin regulation and cellular processes. Understanding ECM5 function contributes to fundamental knowledge about eukaryotic gene regulation and cellular responses to environmental conditions. Research utilizing ECM5 antibodies can help elucidate these pathways through detection and quantification of the protein in various experimental conditions.
ECM5 antibody should be stored at -20°C or -80°C upon receipt . Repeated freeze-thaw cycles should be avoided as they can compromise antibody function. For working solutions, aliquoting the antibody and storing the aliquots is recommended to maintain integrity and functionality of the antibody over time.
According to the available data, ECM5 antibody has been tested and validated for ELISA and Western blotting applications . When planning experiments, researchers should consider these validated applications first, while being aware that optimization might be required for their specific experimental conditions.
To verify specificity, researchers should consider:
Performing blocking experiments with recombinant ECM5 protein
Using ECM5 knockout/deletion strains as negative controls
Testing cross-reactivity with related proteins
Comparing results from multiple antibody clones or sources
The polyclonal nature of available ECM5 antibodies means they recognize multiple epitopes, potentially increasing sensitivity but requiring careful validation of specificity.
When working with yeast cell lysates, researchers should consider:
| Challenge | Solution |
|---|---|
| Cell wall interference | Optimize lysis buffers with appropriate enzymes (lyticase, zymolyase) |
| High background | Use blocking agents specific for yeast proteins (e.g., 5% non-fat milk with yeast lysate pre-absorption) |
| Protein degradation | Include appropriate protease inhibitors specific for yeast proteases |
| Low signal | Consider enrichment techniques before antibody application |
Careful sample preparation is essential for successful detection of ECM5 in yeast systems.
For studying ECM5 protein interactions, researchers could:
Perform co-immunoprecipitation followed by mass spectrometry
Use the antibody in chromatin immunoprecipitation (ChIP) assays to identify DNA binding sites
Employ proximity ligation assays (PLA) for in situ detection of protein complexes
Conduct yeast two-hybrid screens with validation using the antibody
When developing such methods, optimization of antibody concentration and buffer conditions would be critical for success.
For optimal Western blot detection of ECM5:
Sample preparation: Use denaturing conditions with SDS and reducing agents; optimize lysis buffers for yeast cells
Gel selection: Consider the predicted molecular weight of ECM5 (~185 kDa) when selecting gel percentage
Transfer conditions: Longer transfer times or specialized methods for higher molecular weight proteins
Antibody dilution: Start with manufacturer recommendations (typically 1:1000) and optimize
Detection system: Enhanced chemiluminescence systems typically provide good sensitivity
The antibody's specific storage buffer (50% Glycerol, 0.01M PBS, pH 7.4 with 0.03% Proclin 300) should be considered when calculating final dilutions.
Although immunofluorescence is not specifically listed among tested applications for the ECM5 antibody in the available data , researchers attempting this application should implement:
Positive control: Wild-type yeast cells with known ECM5 expression
Negative control: ECM5 deletion strain or cells treated with ECM5 siRNA
Secondary antibody-only control: To assess non-specific binding
Pre-absorption control: Pre-incubating antibody with recombinant ECM5
Peptide competition: Using the immunizing peptide to block specific binding
These controls help distinguish true signal from background and confirm antibody specificity.
Different fixation methods can significantly impact epitope accessibility:
| Fixation Method | Advantages | Considerations for ECM5 Detection |
|---|---|---|
| Paraformaldehyde | Preserves morphology | May mask epitopes, requiring retrieval |
| Methanol | Good for nuclear proteins | Can destroy some epitopes |
| Acetone | Minimal epitope masking | May not preserve cellular structures |
| Glutaraldehyde | Strong fixation | High autofluorescence, potential epitope alteration |
Researchers should test multiple fixation protocols when establishing ECM5 detection methods.
To study ECM5's role in chromatin regulation:
Chromatin immunoprecipitation (ChIP) assays to identify DNA binding sites
Co-immunoprecipitation with histone modifiers and chromatin remodelers
Immunofluorescence to examine nuclear localization under different conditions
Western blotting to assess protein levels during different cell cycle stages
These approaches should be complemented with functional assays to correlate ECM5 binding with biological outcomes.
For quantitative applications:
Establish a standard curve using recombinant ECM5 protein
Determine the linear range of detection for the antibody
Use appropriate normalization controls (housekeeping proteins)
Consider the impact of post-translational modifications on antibody recognition
Account for potential lot-to-lot variations by testing each new antibody lot
Quantitative comparisons should always be performed with samples processed identically and ideally on the same blot or plate.
Integration of antibody-based detection with genetic approaches enhances research rigor:
Confirm knockout efficiency in deletion strains via Western blotting
Verify tagged constructs expression and functionality
Assess localization changes in mutant strains
Monitor protein levels in response to genetic perturbations
Validate genetic interaction findings with protein interaction studies
This combined approach provides multiple lines of evidence for ECM5 function and regulation.
Potential advanced applications include:
Super-resolution microscopy to examine sub-nuclear localization
Live-cell imaging using antibody fragments
Antibody-based proximity labeling for proteomic analysis
ELISA-based high-throughput screening of ECM5 modulators
Single-cell Western blotting for heterogeneity analysis
Each application would require specific optimization and validation strategies.
For cross-species analysis:
Test cross-reactivity with ECM5 homologs in related fungal species
Use epitope mapping to identify conserved regions
Consider developing pan-ECM5 antibodies targeting highly conserved domains
Implement computational approaches to predict cross-reactivity
Such studies could reveal evolutionary conservation of ECM5 function and regulation.
Emerging technologies that could enhance ECM5 research include:
Single-molecule detection methods
Nanobody development for improved penetration
Multiplex imaging with other chromatin regulators
Mass cytometry for single-cell protein quantification
Recombinant antibody technologies for improved reproducibility
Researchers should monitor the literature for developments in these areas that could be applied to ECM5 studies.